Q3 2020 Calliditas Therapeutics AB Earnings Call Transcript
Ladies and gentlemen welcome to the Calliditas Therapeutics Q3 2020.
Today, I'm pleased to present CEO, Renee Lucander; and CFO, Fredrik Johansson.
(Operator Instructions)
Speakers, please begin.
()-
Thank you. Thank you, and welcome to this Q3 2020 report from Calliditas Therapeutics.
I'm going to start this on Page 3. So Calliditas, as you know, is a late-stage biopharma company focused on treatments in orphan indications.
Our lead candidate Nefecon is a novel investigational treatment for IgA nephropathy, intended to be disease-modifying. We're doing that by delivering medication locally, which targets the origin of the disease rather than systemically as most of everybody else who's looking at this area.
We have, as many of you would know, recently reported out our successful Part A of our Phase III clinical trial in NefIgArd, where we reached both primary and secondary endpoints.
The
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
